South African Equine Veterinary Association Congress 2015 Protea Hotel Stellenbosch
McGowan CM, Frost R, Pfeiffer DU, et al. Serum insulin concentrations in horses with equine
Cushing‟s syndrome: response to a cortisol inhibitor and prognostic value. Equine Vet J
2004;36:295.
Copas VEN, Durham AE. Circannual variation in plasma adrenocorticotropic hormone
concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia
dysfunction. Equine Vet J 2012;44:440.
Treatment
Donaldson MT, LaMonte BH, Morresey P, et al. Treatment with pergolide or cyproheptadine of
pituitary pars intermedia dysfunction (equine Cushing‟s disease). J Vet Int Med 2002;16:743.
Perkins GA, Lamb S, Erb HN, et al. Plasma adrenocorticotropin (ACTH) concentrations and
clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.
Equine Vet J 2002;34:679.
Schott HC, Graves EA, Refsal KR, et al. Diagnosis and treatment of pituitary pars intermedia
dysfunction (classical Cushing‟s disease) and metabolic syndrome (peripheral Cushing‟s
syndrome) in horses. Advances in Vet Derm 2005;5:159.
Beech J. Treatment of hypophysial adenomas. Compend Cont Educ Pract Vet 1994;16:921.
Peters DF, Erfle JB, Slobojan GT. Low-dose pergolide mesylate treatment for equine hypophyseal
adenomas (Cushing‟s syndrome), in Proceedings. Am Assoc Equine Pract 1995;41:154.
McGowan CM, Neiger R. Efficacy of trilostane for the treatment of equine Cushing‟s syndrome.
Equine Vet J 2003;35:414.
Beech J, Donaldson MT, Lindborg S. Comparison of Vitex agnus castus extract and pergolide in
treatment of equine Cushing‟